Quantcast

Latest Thalidomide Stories

2008-10-30 09:00:40

Revlimid has become the latest in a series of oncology drugs that have failed to satisfy NICE's cost-effectiveness criteria. As a result, Celgene's drug will not be available to multiple myeloma patients on the UK's National Health Service. The regulatory decision will restrict Revlimid's commercial potential with patients now likely to be switched to other treatments such as Thalomid and Velcade. Revlimid (lenalidomide) was approved in combination with dexamethasone for the treatment of...

2008-10-17 09:00:27

Celgene and Acceleron Pharma have initiated a Phase II clinical study of its lead compound ACE-011 in patients with multiple myeloma. Celgene will make a $5 million milestone payment to Acceleron in accordance with the terms of the collaboration agreement between the two companies. The Phase II, multi-center, randomized, double-blind, placebo-controlled study is designed to assess the safety and efficacy of multiple doses of ACE-011 in multiple myeloma patients with osteolytic bone lesions....

2008-10-16 09:00:10

Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 2 clinical study of its lead compound ACE-011 in patients with multiple myeloma. ACE-011 is being developed to treat bone loss associated with multiple myeloma and other cancers. The clinical study is designed to assess the safety and efficacy of ACE-011 in multiple...

2008-10-06 12:00:42

Celgene International, a wholly owned subsidiary of Celgene Corporation, has announced that its oral cancer drug Revlimid has received marketing authorization approval from Health Canada for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. The authorization from Health Canada was based upon the safety and efficacy results of two large, randomized pivotal Phase III special protocol assessment trials, North...

2008-10-03 18:00:32

Tokyo, Oct. 3 (Jiji Press)--A Japanese Health, Labor and Welfare Ministry panel on Friday approved the production and sale of thalidomide, a controversial sedative-hypnotic banned more than 40 years ago, for the treatment of multiple myeloma, a type of blood cancer, under strict conditions. The Pharmaceutical Affairs and Food Sanitation Council conveyed the decision to Health, Labor and Welfare Minister Yoichi Masuzoe later in the day. The minister is expected to give his final go- ahead...

2008-09-29 09:00:57

The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - today heralded the expansion of treatment options for previously untreated patients with multiple myeloma, giving patients in Canada and Europe access to drugs similar to what is available to patients in the United States. The announcement, made on September 8, 2008 by the European Commission, provides for the...

2008-09-24 03:00:09

By Jones, D Beyond Thalidomide: Birth defects explained. Edited by J. McCredie Pp. 418. Royal Society of Medicine Press Ltd. 2007. ISBN: 13: 978-1-85315-741-7. Pounds 35. It was a pleasure to read this outstanding and scholarly monograph, the fruit of Professor Janet McCredie's 30 years' experience in the field. The book puts together beautifully, through clear prosem excellent illustrations and an extensitve bibliography, the story of thalidomide and the spin-offs there from. In the...

2008-09-05 06:00:23

Elan and Biogen Idec have initiated the first clinical trial of Tysabri in oncology. The first dose of Tysabri was administered earlier in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of Tysabri in patients with relapsed or refractory multiple myeloma. This Phase I/II, open-label, two-arm study is designed to evaluate the safety and anti-tumor activity of Tysabri in patients with relapsed or refractory multiple myeloma. In...

2008-09-05 03:00:28

Celgene, which discovers, develops and commercializes therapies for the treatment of cancer and inflammatory diseases, has announced that Amrubicin has been granted fast track product designation by the FDA for the treatment of small cell lung cancer after first-line chemotherapy. Amrubicin is a third-generation, synthetic anthracycline analogue that has demonstrated substantial clinical efficacy in the treatment of small cell lung cancer. Amrubicin has been granted orphan-drug designation...

2008-09-05 00:00:26

By Sadie Gray A cancer sufferer whose primary care trust refused to pay for a drug which could extend his life by up to three years has launched an "end of the road" legal challenge to the decision. If Colin Ross continues to be denied the drug, Revlimid, he will die within a few months, experts say. His lawyers told the High Court yesterday that he was the victim of a postcode lottery. Mr Ross, 55, said his doctors had requested funding for up to four courses of Revlimid at 5,000 a...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related